Dorsey Wright & Associates Buys Shares of 2,001 Thermo Fisher Scientific Inc. $TMO

Dorsey Wright & Associates bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, Holdings Channel.com reports. The institutional investor bought 2,001 shares of the medical research company’s stock, valued at approximately $984,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in TMO. Quadrant Private Wealth Management LLC grew its stake in Thermo Fisher Scientific by 32.4% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 1,830 shares of the medical research company’s stock worth $900,000 after buying an additional 448 shares during the last quarter. Watershed Asset Management L.L.C. lifted its stake in Thermo Fisher Scientific by 29.6% in the first quarter. Watershed Asset Management L.L.C. now owns 7,000 shares of the medical research company’s stock valued at $3,441,000 after buying an additional 1,600 shares during the last quarter. Heartland Bank & Trust Co boosted its holdings in shares of Thermo Fisher Scientific by 29.9% during the first quarter. Heartland Bank & Trust Co now owns 1,928 shares of the medical research company’s stock valued at $948,000 after acquiring an additional 444 shares during the period. Atlas Wealth LLC grew its position in shares of Thermo Fisher Scientific by 804.1% during the first quarter. Atlas Wealth LLC now owns 36,880 shares of the medical research company’s stock worth $18,128,000 after acquiring an additional 32,801 shares during the last quarter. Finally, Cornerstone Planning Group LLC increased its holdings in shares of Thermo Fisher Scientific by 22.6% in the 1st quarter. Cornerstone Planning Group LLC now owns 239 shares of the medical research company’s stock worth $111,000 after acquiring an additional 44 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Trading Down 2.0%

Shares of NYSE:TMO opened at $532.17 on Friday. The company has a 50 day moving average of $484.57 and a 200-day moving average of $514.88. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market cap of $197.77 billion, a P/E ratio of 29.26, a P/E/G ratio of 2.36 and a beta of 0.87. Thermo Fisher Scientific Inc. has a twelve month low of $403.36 and a twelve month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same quarter last year, the business earned $5.15 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.34%.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TMO shares. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a research note on Friday, June 26th. They set a “market perform” rating and a $520.00 target price for the company. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a report on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price objective for the company. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their target price for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Finally, DZ Bank initiated coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They set a “buy” rating and a $610.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $602.14.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.